The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 May 13

PMID 35557620

Authors

Xiang-Yang Bao

Yan-Na Fan

Qian-Nan Wang

Xiao-Peng Wang

Ri-Miao Yang

Zheng-Xing Zou

Qian Zhang

De-Sheng Li

Lian Duan

Xin-Guang Yu

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: To explore the genetic basis and molecular mechanism of native arteriogenesis and therapeutic synangiosis in moyamoya disease (MMD).

Methods: An angiography-based study using patients from a prospective trial of encephaloduroarteriosynangiosis (EDAS) surgery was performed. The spontaneous collaterals grades were evaluated according to the system described by a new grading system. Blood samples were collected from all the recruited patients before EDAS and during the second hospitalization 3 months post-EDAS. We performed Boolean analysis using a combination of specific cell surface markers of CD34CD133CD45KDR. Genotyping of p.R4810K was also performed. The correlation of age, sex, initial symptoms at diagnosis, collateral grade, Suzuki stages, the RNF213 genotype, time to peak (TTP), and endothelial progenitor cell (EPC) count with good collateral circulation was evaluated.

Results: Eighty-five patients with MMD were included in this study. The mutation rate of RNF213 p.R4810K in our study was 25.9% (22/85). The heterozygous mutations were occurred significantly more frequently in the cases that were presented with infarction, worse neurological status, severe posterior cerebral artery (PCA) stenosis, and longer TTP delay. Further, the heterozygous mutations occurred significantly more frequently in the poor collateral stage group. Lower grades were significantly correlated with severe ischemia symptoms, worse neurological status, and a longer TTP delay. The post-operative angiographic findings showed that a good Matsushima grade was correlated with heterozygous mutations, a lower collateral stage, and a longer TTP delay. The CD34CD133CD45KDR cell count in patients 3 months post-EDAS was significantly higher as compared to the count before EDAS in the good Matsushima grade group. However, this change was not observed in the poor Matsushima grade group.

Conclusions: These data imply that mutations of RNF213 p.R4810K affect the establishment of spontaneous collateral circulation, and EPCs are involved in the process of formation of new EDAS collaterals.

Citing Articles

A Novel Interhemispheric Dural Inversion Technique for Indirect Parafalcine Cerebral Revascularization: Case Report.

Atai N, Nguyen V, Kammen A, Sternbach S, Rennert R, Russin J Neurosurg Pract. 2025; 5(2):e00085.

PMID: 39958238 PMC: 11783637. DOI: 10.1227/neuprac.0000000000000085.

Clinical and genetic factors associated with contralateral progression in unilateral moyamoya disease: Longitudinal and Cross-Sectional Study.

Wang X, Zou Z, Bao X, Wang Q, Ren B, Yu D Heliyon. 2024; 10(4):e26108.

PMID: 38404780 PMC: 10884840. DOI: 10.1016/j.heliyon.2024.e26108.

RNF213 in moyamoya disease: Genotype-phenotype association and the underlying mechanism.

Fang J, Yang X, Ni J Chin Med J (Engl). 2024; 137(21):2552-2560.

PMID: 38243713 PMC: 11557053. DOI: 10.1097/CM9.0000000000002985.

To explore the effectiveness of atorvastatin in the postoperative formation of collateral blood vessels after encephaloduroarteriosynangiosis in patients with moyamoya disease: a prospective double-blind randomized controlled study.

Gao G, Wang Q, Hao F, Wang X, Liu S, Wang M Front Neurol. 2023; 14:1169253.

PMID: 37332989 PMC: 10270285. DOI: 10.3389/fneur.2023.1169253.

References

Kim S, Seol H, Cho B, Hwang Y, Lee D, Wang K . Moyamoya disease among young patients: its aggressive clinical course and the role of active surgical treatment. Neurosurgery. 2004; 54(4):840-4. DOI: 10.1227/01.neu.0000114140.41509.14. View

Hirschi K, Ingram D, Yoder M . Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008; 28(9):1584-95. PMC: 5244813. DOI: 10.1161/ATVBAHA.107.155960. View

Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N . Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011; 104(7):1144-50. PMC: 3068506. DOI: 10.1038/bjc.2011.72. View

Djonov V, Makanya A . New insights into intussusceptive angiogenesis. EXS. 2004; (94):17-33. DOI: 10.1007/3-7643-7311-3_2. View

Suzuki J, Takaku A . Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969; 20(3):288-99. DOI: 10.1001/archneur.1969.00480090076012. View

Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A . A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2010; 56(1):34-40. DOI: 10.1038/jhg.2010.132. View

Zhang Q, Zhang D, Wang R, Liu Y, Zhang Y, Wang S . Clinical and Angiographic Features of Patients with Moyamoya Disease and the p.R4810K Heterozygous Variant. World Neurosurg. 2016; 90:530-538.e3. DOI: 10.1016/j.wneu.2015.12.093. View

Choi J, Kim D, Kim E, Lee K . Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups. Clin Neurol Neurosurg. 1997; 99 Suppl 2:S11-8. DOI: 10.1016/s0303-8467(97)00033-4. View

Risau W . Mechanisms of angiogenesis. Nature. 1997; 386(6626):671-4. DOI: 10.1038/386671a0. View

10.

Yoder M . Human endothelial progenitor cells. Cold Spring Harb Perspect Med. 2012; 2(7):a006692. PMC: 3385946. DOI: 10.1101/cshperspect.a006692. View

11.

Koizumi A, Kobayashi H, Hitomi T, Harada K, Habu T, Youssefian S . A new horizon of moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med. 2015; 21(2):55-70. PMC: 4771639. DOI: 10.1007/s12199-015-0498-7. View

12.

Carmeliet P . Cardiovascular biology. Creating unique blood vessels. Nature. 2001; 412(6850):868-9. DOI: 10.1038/35091178. View

13.

Solder E, Bockle B, Nguyen V, Furhapter C, Obexer P, Erdel M . Isolation and characterization of CD133+CD34+VEGFR-2+CD45- fetal endothelial cells from human term placenta. Microvasc Res. 2012; 84(1):65-73. DOI: 10.1016/j.mvr.2012.03.005. View

14.

Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S . Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study. J Neurosurg. 2017; 128(5):1327-1337. DOI: 10.3171/2016.12.JNS162626. View

15.

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4):434-8. DOI: 10.1038/7434. View

16.

Duan L, Wei L, Tian Y, Zhang Z, Hu P, Wei Q . Novel Susceptibility Loci for Moyamoya Disease Revealed by a Genome-Wide Association Study. Stroke. 2017; 49(1):11-18. DOI: 10.1161/STROKEAHA.117.017430. View

17.

Duda D, Cohen K, Scadden D, Jain R . A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007; 2(4):805-10. PMC: 2686125. DOI: 10.1038/nprot.2007.111. View

18.

Derdeyn C . Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009; 361(1):97. DOI: 10.1056/NEJMc090780. View

19.

Saito N, Imai H . Insights on the revascularization mechanism for treatment of Moyamoya disease based on the histopathologic concept of angiogenesis and arteriogenesis. World Neurosurg. 2011; 75(2):204-5. DOI: 10.1016/j.wneu.2010.10.004. View

20.

. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012; 52(5):245-66. DOI: 10.2176/nmc.52.245. View